

# UNAUDITED INTERIM RESULTS

for the six months ended 31 December 2024  
and cash dividend declaration



TOP RANKED PHARMACEUTICAL COMPANY  
IN THE SOUTH AFRICAN PRIVATE MARKET

## Introduction

The Group's operational and financial performance during the period under review ended below expectations, driven by several sector-specific factors, including constrained consumer spending within the lower LSM's and reduced inventory holdings in the pharmaceutical wholesale channel, evidenced by their sales into pharmacies being higher than orders placed on the Company. The reduced demand adversely impacted the gross margin due to significantly reduced production levels in the period, particularly at the Wadeville facility.

The Board of Directors (Board) is pleased to report that Adcock Ingram is now a certified Level 1 B-BBEE contributor.

## Prospects

The implementation of an SEP adjustment of 5.25% in February 2025 will assist in countering the gross margin pressure, but we do not foresee that the Wadeville facility will materially increase output in the next six months.

Lower interest rates and reduced inflation should provide some relief to constrained consumers. Nonetheless, we remain concerned about unemployment, the effect of which has an impact on a number of our brands. We expect some recovery in the independent wholesale channel, and envisage a movement towards normal inventory holdings in at least one of our large pharmaceutical wholesale customers.

Management remains committed to seeking additional affordable brands to expand the non-price-regulated portfolio and pursuing further partnerships with multinational pharmaceutical companies as they evaluate their front-end models in South Africa.

		Change %	Unaudited six-month period ended 31 December 2024	Unaudited six-month period ended 31 December 2023
Revenue	(R'000)	(1)	<b>4 714 234</b>	4 740 424
Gross profit	(R'000)	(5)	<b>1 535 606</b>	1 609 667
Operating profit	(R'000)	(17)	<b>487 328</b>	585 747
Headline earnings per share	(cents)	(9)	<b>265.5</b>	293.0
Basic earnings per share	(cents)	(9)	<b>265.5</b>	291.3
Total assets	(R'000)		<b>8 743 013</b>	8 329 023
Net asset value per share	(cents)		<b>3 777.5</b>	3 625.8
Dividend declared per share	(cents)		<b>115.0</b>	125.0
<b>Segment revenue</b>				
Consumer	(R'000)	1	<b>870 539</b>	866 028
OTC	(R'000)	(4)	<b>1 101 971</b>	1 149 370
Prescription	(R'000)	(5)	<b>1 625 661</b>	1 712 894
Hospital	(R'000)	10	<b>1 115 452</b>	1 011 992
<b>Segment trading profit</b>				
Consumer	(R'000)	(6)	<b>177 414</b>	188 670
OTC	(R'000)	4	<b>171 852</b>	164 955
Prescription	(R'000)	(52)	<b>89 884</b>	189 131
Hospital	(R'000)	-	<b>74 238</b>	74 198

## Cash dividend declaration

The Board has declared a final gross dividend out of income reserves of 115 cents per share in respect of the six-months ended 31 December 2024. The South African dividend tax ("DT") rate is 20% and the net dividend payable to shareholders who are not exempt from DT is 92 cents per share. Adcock Ingram currently has 161 300 000 ordinary shares in issue and qualifying for ordinary dividends. The income tax reference number is 9528/919/15/3.

The salient dates for the distribution are detailed below:

Last date to trade cum distribution	Tuesday, 11 March 2025
Shares trade ex distribution	Wednesday, 12 March 2025
Record date	Friday, 14 March 2025
Payment date	Monday, 17 March 2025

Share certificates may not be dematerialised or rematerialised between Wednesday, 12 March 2025 and Friday, 14 March 2025, both dates inclusive.

**N Madisa**  
Chairperson

**AG Hall**  
Chief Executive Officer

Approved by the Board: 19 February 2025

SENS release date: 20 February 2025

**Adcock Ingram Holdings Limited** (Incorporated in the Republic of South Africa) (Registration number 2007/016236/06)  
**Share code:** AIP **ISIN:** ZAE000123436 ("**Adcock Ingram**" or "**the Company**" or "**the Group**") **Company secretary** M Phalafala  
**Registered office** 1 New Road, Midrand, 1682 **Postal address** Private Bag X69, Bryanston, 2021 **Transfer secretaries** Computershare Investor Services Proprietary Limited, Rosebank Towers, 15 Biermann Avenue, Rosebank, Johannesburg, 2196. Private Bag X9000, Saxonwold, 2132 **Auditors** PricewaterhouseCoopers Inc, 4 Lisbon Lane, Waterfall, 2090 **Sponsor** Rand Merchant Bank (a division of FirstRand Bank Limited), 1 Merchant Place, corner Fredman Drive and Rivonia Road, Sandton, 2196 **Bankers** Nedbank Limited, 135 Rivonia Road, Sandown, Sandton, 2146. Rand Merchant Bank, 1 Merchant Place, corner Fredman Drive and Rivonia Road, Sandton, 2196. Investec Bank Limited, 100 Grayston Drive, Sandton, 2146

The unaudited interim results for the 6 months ended 31 December 2024 ("interim results") have been published on SENS and are available at <https://senspdf.jse.co.za/documents/2025/JSE/ISSE/AIP/AIP012025.pdf>. The contents of this results announcement are the responsibility of the Board of Directors. As this results announcement does not contain full details, any investment decision should be based on the contents of the information contained in the interim results, which are also available on the Company's website at [www.adcock.com/investors/financialreports](http://www.adcock.com/investors/financialreports).